연구동향 분석

Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer

윤지선 강서영 이경훈 천기정 오도연 년

논문상세정보
    • 저자 윤지선 강서영 이경훈 천기정 오도연
    • 제어번호 107362681
    • 학술지명 Cancer Research and Treatment
    • 권호사항 Vol. 53 No. 2 [ 2021 ]
    • 발행처 대한암학회
    • 발행처 URL http://www.cancer.or.kr
    • 자료유형 학술저널
    • 수록면 471-479
    • 언어 English
    • 출판년도 2021
    • 등재정보 KCI등재
    • 소장기관 경북대학교 도서관 의학분관 부산대학교 중앙도서관
    • 판매처
    유사주제 논문( 0)
인용/피인용

' Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer' 의 참고문헌

  • [18F]-FMISO PET study of hypoxia in gliomas before surgery : correlation with molecular markers of hypoxia and angiogenesis
    Bekaert L [2017]
  • Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent
    Hicks RJ [2005]
  • Tumor hypoxia detected by(18)F-fluoromisonidazole positron emission tomography(FMISO PET)as a prognostic indicator of radiotherapy(RT)
    Tachibana I [2018]
  • Tumor hypoxia : definitions and current clinical, biologic, and molecular aspects
    Hockel M [2001]
  • Tumor hypoxia : a new PET imaging biomarker in clinical oncology
    Tamaki N [2016]
  • TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy : optimization of dosing regimens and schedules
    Liu Q [2012]
  • Secondline chemotherapy in advanced biliary cancer : a systematic review
    Lamarca A [2014]
  • Second-line therapy in advanced biliary tract cancer: what should be the standard?
    Cereda S [2013]
  • Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination : a large multicenter study by the Association des Gastro-Enterologues Oncologues
    Brieau B [2015]
  • Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas
    Szeto MD [2009]
  • PET radiopharmaceuticals for imaging of tumor hypoxia : a review of the evidence
    Lopci E [2014]
  • Molecular and cellular pharmacology of the hypoxiaactivated prodrug TH-302
    Meng F [2012]
  • Metabolism and excretion of TH-302 in dogs
    Jung D [2012]
  • Hypoxia-induced PLOD2 is a key regulator in epithelial-mesenchymal transition and chemoresistance in biliary tract cancer
    Okumura Y [2018]
  • Hypoxia enhances cholangiocarcinoma invasion through activation of hepatocyte growth factor receptor and the extracellular signalregulated kinase signaling pathway
  • Gallbladder cancer worldwide : geographical distribution and risk factors
    Randi G [2006]
  • FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer
    Thureau S [2018]
  • Combined use of(18)F-FDG and(18)FFMISO in unresectable non-small cell lung cancer patients planned for radiotherapy : a dynamic PET/CT study
  • Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer
    Valle J [2010]
  • Biliary tract cancers : epidemiology, molecular pathogenesis and genetic risk associations
  • Biliary tract cancers
    de Groen PC [1999]
  • Advantage of FMISO-PET over FDG-PET for predicting histological response to preoperative chemotherapy in patients with oral squamous cell carcinoma
    Sato J [2014]
  • A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma : a multicentre, multinational study
    Yi JH [2012]
  • A comparative study of the hypoxia PET tracers(18)F-HX4, (18)F-FAZA, and(18)F-FMISO in a preclinical tumor model
    Peeters SG [2015]